Mindblown: a blog about philosophy.

Investing.com – India stocks were lower after the close on Tuesday, as losses in the IT, Consumer Durables and Technology sectors led shares lower. At the close in NSE, the Nifty 50 declined 0.42%, while the BSE Sensex 30 index fell 0.50%. The best performers of the session on the Nifty 50 were Coal India […]

Spero Therapeutics (NASDAQ:SPRO) has disclosed its financial results for the third quarter of 2023 and provided a notable pipeline update. The company announced a written agreement with the FDA for the design and size of its upcoming Phase III trial of Tebipenem HBr, an oral carbapenem antibiotic in development for complicated urinary tract infections (CUTI). […]

Investing.com – India stocks were lower after the close on Tuesday, as losses in the IT, Consumer Durables and Technology sectors led shares lower. At the close in NSE, the Nifty 50 declined 0.42%, while the BSE Sensex 30 index fell 0.50%. The best performers of the session on the Nifty 50 were Coal India […]

Spero Therapeutics (NASDAQ:SPRO) has disclosed its financial results for the third quarter of 2023 and provided a notable pipeline update. The company announced a written agreement with the FDA for the design and size of its upcoming Phase III trial of Tebipenem HBr, an oral carbapenem antibiotic in development for complicated urinary tract infections (CUTI). […]

Investing.com – India stocks were lower after the close on Tuesday, as losses in the IT, Consumer Durables and Technology sectors led shares lower. At the close in NSE, the Nifty 50 declined 0.42%, while the BSE Sensex 30 index fell 0.50%. The best performers of the session on the Nifty 50 were Coal India […]

Spero Therapeutics (NASDAQ:SPRO) has disclosed its financial results for the third quarter of 2023 and provided a notable pipeline update. The company announced a written agreement with the FDA for the design and size of its upcoming Phase III trial of Tebipenem HBr, an oral carbapenem antibiotic in development for complicated urinary tract infections (CUTI). […]

Zomedica Corp. (NYSE American: ZOM) reported record revenues of $6.3 million in its third quarter 2023 earnings call, marking a 31% increase over the same period last year. The company attributed this growth to organic expansion and the successful integration of its recent acquisitions. Key takeaways from the call: The third quarter also saw the […]

XP (NASDAQ:XP) Inc. delivered strong results in the third quarter of 2023, reporting increased top line growth and profitability, according to its recent earnings call. The company ended the quarter with BRL1.1 trillion in client assets, reaching all-time high records in most investment metrics. The company also announced the acquisition of Modal, with plans for […]

Zomedica Corp. (NYSE American: ZOM) reported record revenues of $6.3 million in its third quarter 2023 earnings call, marking a 31% increase over the same period last year. The company attributed this growth to organic expansion and the successful integration of its recent acquisitions. Key takeaways from the call: The third quarter also saw the […]

XP (NASDAQ:XP) Inc. delivered strong results in the third quarter of 2023, reporting increased top line growth and profitability, according to its recent earnings call. The company ended the quarter with BRL1.1 trillion in client assets, reaching all-time high records in most investment metrics. The company also announced the acquisition of Modal, with plans for […]